|
|
|
|
|
|||||||
|
Session 13
Oral Abstract Session
Antiretroviral Chemotherapy: Combination Therapy, Drug Resistance, and Treatment Interruption Tuesday, 10 am - 12:30 pm 4B |
| Moderators |
Bonaventura Clotet, Fndn. Irsicaixa, Badalona, Spain and Margaret Fischl,
Univ. of Miami Sch. of Med., FL | ||
| 10:00 41. | A Randomized Trial Comparing 2 4-Drug Antiretroviral Regimens with a 3-Drug Regimen in Advanced HIV Disease M. Fischl*1, H. Ribaudo2, A. C. Collier3, A. Erice4, M. Giuliano5, M. Dehlinger6, J. J. Eron7, M. Saag8, S. Hammer9, S. Vella5, and J. Feinberg10 for the AIDS Clinical Trials Group 388 Team 1Univ. of Miami, FL; 2Harvard Univ., Boston, MA; 3Univ. of Washington, Seattle; 4Univ. of Minnesota, Minneapolis; 5Inst. Superiore, Rome, Italy; 6NIAID, NIH, Bethesda, MD; 7Univ. of North Carolina, Chapel Hill; 8Univ. of Alabama, Birmingham; 9Columbia Univ. Coll. of Physicians and Surgeons, New York, NY; and 10Univ. of Cincinnati, OH
| ||
| 10:15 42. | Atazanavir Plus Saquinavir Once Daily Favorably Affects Total Cholesterol (TC), Fasting Triglyceride (TG), and Fasting LDL Cholesterol (LDL) Profiles in Patients Failing Prior Therapy (Trial AI424-009, Week 48) D. W. Haas*1, C. Zala2, S. Schrader3, A. Thiry4, R. McGovern4, and S. Schnittman4 1Vanderbilt Univ., Nashville, TN; 2Fndn. Hosp., Buenos Aires, Argentina; 3HCRN/Montrose Clin., Houston, TX; and 4Bristol-Myers Squibb, Wallingford, CT
| ||
| 10:30 43. | Effect of Baseline Nucleoside-Associated Resistance on Response to Tenofovir DF (TDF) Therapy: Integrated Analyses of Studies 902 and 907 M. D. Miller*, N. A. Margot, and B. Lu Gilead Sci., Foster City, CA
| ||
| 10:45 44. | Crystal Structure of HIV-1 RT with Template-Primer Terminated with the Acyclic Nucleotide RT Inhibitor Tenofovir Suggests Mechanisms of Evading Resistance S. Tuske*1, S. Sarafianos1, A. D. Clark Jr.1, J. Ding1, L. K. Naeger2, M. D. Miller2, C. Gibbs2, D. M. Jerina3, S. Hughes4, and E. Arnold1 1 Ctr. for Advanced Biotechnology and Med. and Rutgers Univ., Piscataway, NJ; 2 Gilead Sci., Foster City, CA; 3NIDDK, NIH, Bethesda, MD; and 4 NCI, NIH, Frederick, MD
| ||
| 11:00 45. | Efavirenz Hypersusceptibility Improves Virologic Response to Multidrug Salvage Regimens in ACTG 398 J. Mellors*1, F. Vaida2, K. Bennett2, N. S. Hellmann3, V. DeGruttola2, and S. Hammer4 for the ACTG 398 Study Team 1Univ. of Pittsburgh, PA; 2Harvard Sch. of Publ. Hlth., Boston, MA; 3ViroLogic, San Francisco, CA; and 4Columbia Univ., New York, NY
| ||
| 11:15 46. | Different Pathways to Nelfinavir Genotypic Resistance in HIV-1 Subtypes B and G P. Gomes, I. Diogo, M. F. Gonçalves, P. Carvalho, J. Cabanas, M. C. Lobo, and R. Camacho* Hosp. Egas Moniz, Lisbon, Portugal
| ||
| 11:30 47. | Drug Resistant Replication Competent HIV-1 Occurs Initially in the CD45RO Subset of CD4 T Cells and Subsequently in CD45RA CD4 Lymphocytes Following Antiretroviral Therapy S. Rose*, E. Perez, S. Lamers, J. Sleasman, and M. Goodenow Univ. of Florida Coll. of Med., Gainesville
| ||
| 11:45 48. | Interruption/Stopping Antiretroviral Therapy and the Risk of Clinical Disease: Results from the EuroSIDA Study. J. D. Lundgren*, S. Vella, L. Paddam, A. Blaxhult, N. Vetter, N. Clumeck, G. Panos, M. Fisher, C. Katlama, and A. N. Phillips EuroSIDA Coord Office, Hvidovre, Denmark
| ||
| 12:00 49. | Dynamics of HIV Rebound in Cerebrospinal Fluid (CSF) after Interruption of Antiretroviral Therapy (ART) R. J. Ellis*1, S. Letendre1, S. D. W. Frost2, A. J. Leigh Brown1,2, M. E. Childers1, J. A. McCutchan1, and HIV Neurobehavioral Res. Ctr. 1Univ. of California, San Diego and 2Univ. of Edinburgh, UK
| ||
| 12:15 50. | Viral Populations Emerging in Plasma during Sequential Structured Treatment Interruptions in Chronically HIV-Infected Individuals Are Genetically Distinct between Time-Points and Tissues J. Martinez-Picado*1, S. D. W. Frost2, S. Marfil1, T. Puig1, B. Clotet1, and L. Ruiz1 1irsiCaixa Fndn., Badalona, Spain and 2Univ. of California, San Diego
|
